SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Morson BC. Genesis of colorectal cancer. Clin Gastroenterol 1976; 5: 50525.
  • 2
    Morson BC. The evolution of colorectal carcinoma. Clin Radiol 1984; 35: 42531.
  • 3
    Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 52532.
  • 4
    Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 225170.
  • 5
    Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JDF. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res 1999; 32: 1333.
  • 6
    Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, Waye JD, Bond J, Schapiro M, Stewart ET, Panish J, Ackroyd F, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps: the National Polyp Study Workgroup. N Engl J Med 1993; 328: 9016.
  • 7
    Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, et al. Prevention of colorectal cancer by colonoscopic polypectomy: the National Polyp Study Workgroup. N Engl J Med 1993; 329: 197781.
  • 8
    Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 65862.
  • 9
    Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. Natural history of untreated colonic polyps. Gastroenterology 1987; 93: 100913.
  • 10
    Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JDF. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst 2000; 92: 55763.
  • 11
    Loeve F, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JDF. Final report MISCAN-COLON microsimulation model for colorectal cancer: report to the National Cancer Institute Project No. NO1-CN55186. Rotterdam: Department of Public Health, Erasmus University, 1998.
  • 12
    Johnson DA, Gurney MS, Volpe RJ, Jones DM, VanNess MM, Chobanian SJ, Avalos JC, Buck JL, Kooyman G, Cattau EL Jr. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. Am J Gastroenterol 1990; 85: 96974.
  • 13
    DiSario JA, Foutch PG, Mai HD, Pardy K, Manne RK. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men. Am J Gastroenterol 1991; 86: 9415.
  • 14
    Lieberman DA, Smith FW. Screening for colon malignancy with colonoscopy. Am J Gastroenterol 1991; 86: 94651.
  • 15
    Rex DK, Lehman GA, Hawes RH, Ulbright TM, Smith JJ. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 1991; 100: 647.
  • 16
    Koretz RL. Malignant polyps: are they sheep in wolves' clothing? Ann Intern Med 1993; 118: 638.
  • 17
    National Cancer Institute, DCCPC SRP, Cancer Statistics Branch. Surveillance, epidemiology, and end results (SEER) program public use CD-ROM (1973–1998). Released April 2001, based on the August 2000 submission. Bethesda, MD: National Cancer Institute, 2001.
  • 18
    Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983; 118: 86586.
  • 19
    Gyrd-Hansen D, Sogaard J, Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol 1997; 26: 117281.
  • 20
    Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997; 73: 2204.
  • 21
    Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD, Balfour TW, Amar SS, Armitage NC, Moss SM. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. Lancet 1989; 1: 11604.
  • 22
    Kronborg O, Fenger C, Olsen J, Bech K, Søndergaard O. Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989; 24: 599606.
  • 23
    Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective blinded trial of the colonoscopic miss-rate of large colorectal polyps. Gastrointest Endosc 1991; 37: 1257.
  • 24
    Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 248.
  • 25
    Rex DK, Rahmani EY, Haseman JH, Lemmel GT, Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997; 112: 1723.
  • 26
    Diggle PJ, Liang K, Zeger SL. Analysis of longitudinal data. Oxford: Clarendon Press. 1994.
  • 27
    Levin TR, Palitz A, Grossman S, Conell C, Finkler L, Ackerson L, Rumore G, Selby JV. Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999; 281: 16117.
  • 28
    Lotfi AM, Spencer RJ, Ilstrup DM, Melton LJ III. Colorectal polyps and the risk of subsequent carcinoma. Mayo Clin Proc 1986; 61: 33743.
  • 29
    Bertario L, Russo A, Sala P, Pizzetti P, Ballardini G, Andreola S, Spinelli P. Risk of colorectal cancer following colonoscopic polypectomy. Tumori 1999; 85: 15762.
  • 30
    Cole JW, McKalen A, Powell J. The role of ileal contents in the spontaneous regression of rectal adenomas. Dis Colon Rectum 1961; 4: 4138.
  • 31
    Knoernschild H. Growth rate and malignant potential of colonic polyps: early results. Surg Forum 1963; 14: 13742.
  • 32
    Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of polyps in the rectum and colon: recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol 1986; 21: 85362.
  • 33
    Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 13136.
  • 34
    Winawer SJ, Zauber AG, O'Brien MJ, Gottlieb LS, Sternberg SS, Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD, Kurtz RC, Shike M, et al. The National Polyp Study: design, methods, and characteristics of patients with newly diagnosed polyps. Cancer 1992; 70 (Suppl 5): 123645.
  • 35
    Bensen S, Mott LA, Dain B, Rothstein R, Baron J. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps: Polyp Prevention Study group. Am J Gastroenterol 1999; 94: 1949.
    Direct Link:
  • 36
    Hofstad B, Vatn MH, Andersen SN, Huitfeldt HS, Rognum T, Larsen S, Osnes M. Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut 1996; 39: 44956.
  • 37
    Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 194652.
  • 38
    Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol 2001; 96: 19017.
    Direct Link:
  • 39
    Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 195461.
  • 40
    Khandker RK, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB, Baine WB. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000; 16: 799810.
  • 41
    Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 57384.